Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Oct 4

PMID 34603291

Citations 12

Authors

Jerome Hadjadj

Marie-Louise Fremond

Benedicte Neven

Affiliations

Soon will be listed here.

Abstract

Among inborn errors of immunity (IEIs), some conditions are characterized by inflammation and autoimmunity at the front line and are particularly challenging to treat. Monogenic diseases associated with gain-of-function mutations in genes critical for cytokine signaling through the JAK-STAT pathway belong to this group. These conditions represent good candidates for treatment with JAK inhibitors. Type I interferonopathies, a group of recently identified monogenic auto-inflammatory diseases characterized by excessive secretion of type I IFN, are also good candidates with growing experiences reported in the literature. However, many questions remain regarding the choice of the drug, the dose (in particular in children), the efficacy on the various manifestations, the monitoring of the treatment, and the management of potent side effects in particular in patients with infectious susceptibility. This review will summarize the current experiences reported and will highlight the unmet needs.

Citing Articles

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet's disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol.

Geertsema-Hoeve B, van Laar J, Raaphorst J, Tas S, Welsing P, Goekoop R BMJ Open. 2025; 15(2):e089827.

PMID: 39915014 PMC: 11815459. DOI: 10.1136/bmjopen-2024-089827.

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors.

Du S, Fang Y, Zhang W, Rao G Curr Med Chem. 2024; 31(20):2900-2920.

PMID: 38904160 DOI: 10.2174/0929867330666230324163414.

Intractable diarrhea in an infant-autoimmune enteropathy: A case report.

Tetarbe S, Shah K, Shah I JPGN Rep. 2024; 5(1):70-73.

PMID: 38545278 PMC: 10964334. DOI: 10.1002/jpr3.12038.

Differential Diagnosis: Hepatic Complications in Inborn Errors of Immunity.

Zinser E, Tan K, Kim D, OBrien R, Winstanley A, Yong P J Clin Med. 2023; 12(23).

PMID: 38068532 PMC: 10707526. DOI: 10.3390/jcm12237480.

The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities - proceedings from the IPOPI global multi-stakeholders' summit (June 2022).

Tadros S, Prevot J, Meyts I, Sanchez-Ramon S, Erwa N, Fischer A Front Immunol. 2023; 14:1245718.

PMID: 37654496 PMC: 10465327. DOI: 10.3389/fimmu.2023.1245718.

References

Koskela H, Eldfors S, Ellonen P, van Adrichem A, Kuusanmaki H, Andersson E . Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366(20):1905-13. PMC: 3693860. DOI: 10.1056/NEJMoa1114885. View

Montealegre Sanchez G, Reinhardt A, Ramsey S, Wittkowski H, Hashkes P, Berkun Y . JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018; 128(7):3041-3052. PMC: 6026004. DOI: 10.1172/JCI98814. View

Pin A, Tesser A, Pastore S, Moressa V, Valencic E, Arbo A . Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. Int J Mol Sci. 2020; 21(20). PMC: 7590237. DOI: 10.3390/ijms21207767. View

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

Winthrop K, Harigai M, Genovese M, Lindsey S, Takeuchi T, Fleischmann R . Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020; 79(10):1290-1297. DOI: 10.1136/annrheumdis-2019-216852. View

Veeravalli V, Dash R, Thomas J, Jayachandra Babu R, Vamsi Madgula L, Srinivas N . Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Saf. 2020; 43(8):711-725. DOI: 10.1007/s40264-020-00938-z. View

Gruber C, Calis J, Buta S, Evrony G, Martin J, Uhl S . Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function. Immunity. 2020; 53(3):672-684.e11. PMC: 7398039. DOI: 10.1016/j.immuni.2020.07.006. View

Kiel M, Velusamy T, Rolland D, Sahasrabuddhe A, Chung F, Bailey N . Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014; 124(9):1460-72. PMC: 4148768. DOI: 10.1182/blood-2014-03-559542. View

Adam S, Simon N, Steffen U, Andes F, Scholtysek C, Muller D . JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med. 2020; 12(530). DOI: 10.1126/scitranslmed.aay4447. View

10.

Huss V, Bower H, Wadstrom H, Frisell T, Askling J . Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021; 61(5):1810-1818. PMC: 9071561. DOI: 10.1093/rheumatology/keab570. View

11.

Duncan C, Thompson B, Chen R, Rice G, Gothe F, Young D . Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in . Sci Immunol. 2019; 4(42). PMC: 7115903. DOI: 10.1126/sciimmunol.aav7501. View

12.

Gadina M, Le M, Schwartz D, Silvennoinen O, Nakayamada S, Yamaoka K . Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019; 58(Suppl 1):i4-i16. PMC: 6657570. DOI: 10.1093/rheumatology/key432. View

13.

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

14.

Del Bel K, Ragotte R, Saferali A, Lee S, Vercauteren S, Mostafavi S . JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy Clin Immunol. 2017; 139(6):2016-2020.e5. DOI: 10.1016/j.jaci.2016.12.957. View

15.

Novikova D, Udachkina H, Markelova E, Kirillova I, Misiyuk A, Demidova N . Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int. 2019; 39(7):1181-1189. DOI: 10.1007/s00296-019-04303-x. View

16.

Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg M . Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124(12):5516-20. PMC: 4348945. DOI: 10.1172/JCI79100. View

17.

Chaimowitz N, Ebenezer S, Hanson I, Anderson M, Forbes L . STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition. N Engl J Med. 2020; 383(15):1494-1496. DOI: 10.1056/NEJMc2022226. View

18.

Beauverd Y, Samii K . Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol. 2014; 100(5):498-501. PMC: 7100122. DOI: 10.1007/s12185-014-1628-5. View

19.

Zheng S, Lee P, Wang J, Wang S, Huang Q, Huang Y . Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome. Front Immunol. 2020; 11:985. PMC: 7251162. DOI: 10.3389/fimmu.2020.00985. View

20.

Burmester G, Curtis J, Yun H, FitzGerald O, Winthrop K, Azevedo V . An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020; 43(4):379-392. PMC: 7105422. DOI: 10.1007/s40264-020-00904-9. View